

18 FEBRUARY 2021

LARGE SCALE CANNABIS STUDY LAUNCHED

LGP TO EXCLUSIVELY SUPPLY CANNABIS MEDICINES TO WIDE-RANGING QUALITY OF LIFE STUDY

ASX ANNOUNCEMENT

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) wishes to advise of the media release issued today by the University of Sydney relating to the **QU**ality of life **E**valuation **S**Tudy (“**The QUEST Initiative**”). A copy of that media release is appended to this announcement.

The **QUEST Initiative** aims to be one of the world’s largest longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis.

LGP will exclusively supply medicinal cannabis oil products to enrolled patients as well as providing funding for study costs.

The study, conducted by researchers at the University of Sydney, is for a two-year period and aims to recruit at least 2,100 patients by 30 June 2021. It also has the potential to be extended internationally.

Details of the study can be found in the attached media release from the University of Sydney.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit:
www.computershare.com.au/easyupdate/lgp





THE UNIVERSITY OF
SYDNEY

MEDIA RELEASE

Media Office
sydney.edu.au/news
@SydneyUni_Media

After hours
0402 972 137

Wide-ranging medical cannabis quality-of-life study launches

Major longitudinal study launched to assess changes in quality-of-life outcomes for patients prescribed medicinal cannabis

Researchers at the University of Sydney have launched The QUality of life Evaluation SStudy (The QUEST Initiative), a wide-ranging, longitudinal study for medicinal cannabis patients.

The QUEST Initiative aims to be one of the world's largest studies examining quality of life outcomes in patients prescribed medicinal cannabis. The study aims to recruit at least 2,100 patients¹ by June 2021 with potential to extend this study internationally.

"What makes our study unique is the comprehensive suite of patient-reported outcomes – or PROs – being assessed in patients prescribed medicinal cannabis," said study lead Associate Professor [Claudia Rutherford](#).

The QUEST Initiative seeks to assess changes in patient conditions and symptoms using self-reported quality-of-life outcomes. Information on patient mobility, functionality, pain or discomfort, anxiety and depression, medication requirements and ongoing health costs will be collected and analysed.

The Federal Minister for Health, the Hon. Greg Hunt, commented:

"The QUEST Initiative represents a significant Australian contribution to the global need for reliable, objective and clinically-relevant quality of life data for patients accessing medicinal cannabis treatments for a broad range of chronic conditions.

"It is also commendable to see an entirely home-grown Australian study supported by a leading Australian higher educational institution, advocacy groups and industry participants.

"I would like to congratulate the University of Sydney and study supporters on making such an important clinical contribution and helping to drive increased understanding around medicinal

¹2100 is the minimum sample size (number of recruited patients) calculated to achieve statistical relevance.

cannabis for Australian prescribers and patients - I look forward to reviewing the results of the study in due course.”

About the study

The study is currently open and planned to close in March 2022. It is the first study of a comprehensive suite of quality-of-life measures in Australia of patients prescribed medicinal cannabis for all allowable conditions under the Special Access Scheme.

The study is investigator-led, with principal investigator Associate Professor Claudia Rutherford, deputy director of the [Sydney Quality of Life Office and researcher](#) in the [Faculty of Medicine and Health](#), being responsible for protocol and methodology design, analysis and reporting of study outcomes in line with the study’s ethics approval, Human Research Ethics Committee (HREC).

The QUEST Initiative is guided by an Advisory Group and endorsed by a range of national bodies, such as MS Research Australia, Chronic Pain Australia, Arthritis Australia, Epilepsy Action Australia and Health Insurance Fund of Australia (HIF).

Associate Professor Rutherford noted the study aims were two-fold:

1. To track changes in patient-reported outcomes (PRO) over one year in a large cohort of patients prescribed medicinal cannabis products for a variety of conditions.
2. A secondary objective is to compare differences in PROs between patients who access medical cannabis for different health conditions.

“Medicinal cannabis has been studied in a broad range of chronic conditions and diseases but quality-of-life studies are limited. The QUEST study is unique in its approach, emphasising both health economic and quality of life measures, rather than effectiveness for a specific symptom or condition,” Associate Professor Rutherford said.

“By taking this approach, The QUEST Initiative may be able to provide future critical insights into the health of a patient over time and help us better understand whether the introduction of medicinal cannabis delivers cost-effective improvements to a patient’s wellbeing.”

The study has been designed to accommodate a large cohort of patients with a broad range of chronic conditions and diseases being eligible such as chronic pain, cancer pain, neuropathic pain, insomnia, anxiety, multiple sclerosis and epilepsy.

Declaration

The study is funded by Australian medicinal cannabis manufacturer Little Green Pharma (LGP). LGP provided technical advice on LGP products and their administration, which was incorporated into the study design. Data collection and analysis will be carried out independently.

The study is conducted by researchers at the University of Sydney. It is approved by the University of Sydney’s Human Research Ethics Committee (project number 2020/589).

Media enquiries:

Vivienne Reiner, Media and Public Relations Adviser, University of Sydney – T +61 2 9351 2390 or E vivienne.reiner@sydney.edu.au

David Tasker, Public Relations Advisor, Little Green Pharma – T +61 433 112 936 or E dtasker@chapteroneadvisors.com.au